Search results

Research collaboration with University of Sydney focuses on a personalised approach to cancer treatment.

Radioactive phosphorous for implantable medical device to treat pancreatic cancer in global clinical trial

Excellent radiolabelling facilities and the operation of OPAL, a world-class multi-purpose nuclear reactor, enable ANSTO to produce a large range of radioisotopes for Australian researchers in both radiopharmaceutical and environmental areas.

The final report on the safety of Building 23 by the independent expert review team has been completed.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.

Congress marks watershed moment for nuclear medicine and ANSTO

In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.

ANSTO’s OPAL multi-purpose research reactor at Lucas Heights has officially returned to power and recommenced operations, following a months-long planned shutdown to carry out essential maintenance and upgrades.

Australian Nuclear Science and Technology Organisation (ANSTO) is committed to protecting your personal information in accordance with the Privacy Act 1988 (Cth) (Privacy Act) and the Australian Privacy Principles.

It's ANSTO's role to keep Australia across the very latest developments in nuclear science and technology from around the world. Part of this responsibility is keeping us abreast of the latest developments in nuclear power technologies.

Award recipients Dr Richard Garrett and Dr Nigel Lengkeek with Dr Tien Pham will deliver a Distinguished Lecture on 15 November at ANSTO.

Radiation can be described as energy or particles from a source that travel through space or other mediums. Light, heat, and wireless communications are all forms of radiation.

Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.